Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease
暂无分享,去创建一个
[1] E. Solito,et al. The Impact of Ageing on the CNS Immune Response in Alzheimer’s Disease , 2021, Frontiers in Immunology.
[2] P. Scheltens,et al. Aducanumab: Appropriate Use Recommendations , 2021, The Journal of Prevention of Alzheimer's Disease.
[3] M. Eriksdotter,et al. Cerebrospinal fluid inflammatory markers in Alzheimer's disease: influence of comorbidities. , 2021, Current Alzheimer Research.
[4] M. Memo,et al. A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages , 2020, Journal of personalized medicine.
[5] D. Baltriukienė,et al. The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame? , 2020, Nutrients.
[6] A. Słowik,et al. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. , 2020, Current Alzheimer research.
[7] G. Nunnari,et al. Postsynaptic damage and microglial activation in AD patients could be linked CXCR4/CXCL12 expression levels , 2020, Brain Research.
[8] A. Cianciulli,et al. The Regulatory Role of IL-10 in Neurodegenerative Diseases , 2020, Biomolecules.
[9] I. Lindberg,et al. A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease , 2020, Clinical Proteomics.
[10] M. O’Banion,et al. Evaluating the Effect of Interleukin-4 in the 3xTg Mouse Model of Alzheimer’s Disease , 2020, Frontiers in Neuroscience.
[11] D. Hadjipavlou-Litina,et al. Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids , 2020, International journal of molecular sciences.
[12] I. Mook‐Jung,et al. Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review , 2019, BMB reports.
[13] T. Ozben,et al. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. , 2019, Clinical biochemistry.
[14] I. Mook‐Jung,et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model , 2019, Gut.
[15] F. Trousse,et al. Knockdown of the CXCL12/CXCR7 chemokine pathway results in learning deficits and neural progenitor maturation impairment in mice , 2019, Brain, Behavior, and Immunity.
[16] M. Nguyen,et al. Metal Ions in Alzheimer's Disease: A Key Role or Not? , 2019, Accounts of chemical research.
[17] Dongfang Zhang,et al. Natural products as a potential modulator of microglial polarization in neurodegenerative diseases. , 2019, Pharmacological research.
[18] J. Palha,et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline , 2019, Neurobiology of Aging.
[19] D. Y. Lee,et al. Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals , 2019, Neurobiology of Aging.
[20] Jeffrey L. Cummings,et al. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options , 2019, Journal of Alzheimer's disease : JAD.
[21] L. Tan,et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[22] A. Mulak,et al. Brain-Gut-Microbiota Axis in Alzheimer’s Disease , 2019, Journal of neurogastroenterology and motility.
[23] A. Angiolillo,et al. Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression? , 2018, Journal of Neuroinflammation.
[24] J. Wiltfang,et al. Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia , 2018, Acta Neuropathologica Communications.
[25] R. Petersen,et al. The Cross-Sectional and Longitudinal Associations Between IL-6, IL-10, and TNFα and Cognitive Outcomes in the Mayo Clinic Study of Aging. , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.
[26] B. Garner,et al. Understanding the Role of ApoE Fragments in Alzheimer’s Disease , 2018, Neurochemical Research.
[27] J. Kamińska,et al. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[28] C. Luis,et al. Plasma cytokine IL‐6 levels and subjective cognitive decline: preliminary findings , 2018, International journal of geriatric psychiatry.
[29] Alan J. Thomas,et al. Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[30] Matthew R Chapman,et al. The role of microbial amyloid in neurodegeneration , 2017, PLoS pathogens.
[31] I. Ferrer,et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias , 2017, Molecular Neurodegeneration.
[32] A. Bush,et al. Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[33] A. Carvalho,et al. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[34] M. Fakhoury. Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy , 2017, Current neuropharmacology.
[35] Karsten Melcher,et al. Amyloid beta: structure, biology and structure-based therapeutic development , 2017, Acta Pharmacologica Sinica.
[36] J. Clarimón,et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies , 2017, Journal of Neuroinflammation.
[37] M. Gallego,et al. Musicoterapia en la enfermedad de Alzheimer: efectos cognitivos, psicológicos y conductuales , 2017 .
[38] G. Rossi,et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels , 2017, Scientific Reports.
[39] S. Georgopoulos,et al. Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice , 2017, The Journal of Neuroscience.
[40] Kyong Hwan Jin,et al. Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging , 2017, Behavioural Brain Research.
[41] Paul Edison,et al. An early and late peak in microglial activation in Alzheimer’s disease trajectory , 2017, Brain : a journal of neurology.
[42] Matheus Roriz‐Cruz,et al. Cerebrospinal fluid inflammatory markers in amnestic mild cognitive impairment , 2017, Geriatrics & gerontology international.
[43] G. Frisoni,et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly , 2017, Neurobiology of Aging.
[44] M. Heneka,et al. Danger‐associated molecular patterns in Alzheimer’s disease , 2017, Journal of leukocyte biology.
[45] Debomoy K Lahiri,et al. Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. , 2016, Current Alzheimer research.
[46] Zhijun Zhang,et al. Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms , 2016, Neuroscience Bulletin.
[47] Xinwen Zhou,et al. The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ , 2016, Translational Neurodegeneration.
[48] K. Blennow,et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers , 2016, EMBO molecular medicine.
[49] W. Le,et al. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases , 2016, Molecular Neurobiology.
[50] A. Fagan,et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status , 2016, Acta Neuropathologica.
[51] M. Ciebiada,et al. Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment , 2015, Metabolic Brain Disease.
[52] B. Stevens,et al. Microglia Function in Central Nervous System Development and Plasticity. , 2015, Cold Spring Harbor perspectives in biology.
[53] D. Catalucci,et al. Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.
[54] O. Garaschuk,et al. Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.
[55] K. Fukunaga,et al. The extracellular fragment of GPNMB (Glycoprotein nonmelanosoma protein B, osteoactivin) improves memory and increases hippocampal GluA1 levels in mice , 2015, Journal of neurochemistry.
[56] R. Palmer,et al. Serum Interleukin (IL)-15 as a Biomarker of Alzheimer's Disease , 2015, PloS one.
[57] Y. Lee,et al. Association between TNF-α promoter −308 A/G polymorphism and Alzheimer’s disease: a meta-analysis , 2015, Neurological Sciences.
[58] G. Taglialatela,et al. NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease , 2015, Neuron.
[59] Meiping Zhu,et al. Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors. , 2014, International journal of clinical and experimental pathology.
[60] B. Baune,et al. Inflammasomes in neuroinflammation and changes in brain function: a focused review , 2014, Front. Neurosci..
[61] M. Heneka,et al. Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview , 2014, Molecular Neurobiology.
[62] Y. Hattori,et al. Synthesis and evaluation of curcumin derivatives toward an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1. , 2014, Bioorganic & medicinal chemistry letters.
[63] Bradley T. Hyman,et al. Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.
[64] H. Gendelman,et al. CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.
[65] H. Lashuel. Molecular mechanisms for neurodegeneration , 2013 .
[66] Cornelia M. Wilson,et al. Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.
[67] J. Trojanowski,et al. Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.
[68] A. Quintana,et al. Interleukin-6, a Major Cytokine in the Central Nervous System , 2012, International journal of biological sciences.
[69] K. Cain,et al. Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic Stroke , 2012, Stroke.
[70] Zhi-Qin Xi,et al. Altered expression of CX3CL1 in patients with epilepsy and in a rat model. , 2012, The American journal of pathology.
[71] K. Kawahara,et al. Intracerebral microinjection of interleukin-4/interleukin-13 reduces β-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice , 2012, Neuroscience.
[72] Yun-wu Zhang,et al. CutA Divalent Cation Tolerance Homolog (Escherichia coli) (CUTA) Regulates β-Cleavage of β-Amyloid Precursor Protein (APP) through Interacting with β-Site APP Cleaving Protein 1 (BACE1)* , 2012, The Journal of Biological Chemistry.
[73] Mark E. Schmidt,et al. The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[74] Oskar Hansson,et al. CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease , 2012, PloS one.
[75] W. Griffin. Alzheimer's - Looking beyond plaques , 2011, F1000 medicine reports.
[76] T. Kiyota,et al. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice , 2011, Gene Therapy.
[77] P. Caramelli,et al. Chemokines in CSF of Alzheimer's disease patients. , 2011, Arquivos de neuro-psiquiatria.
[78] B. Ray,et al. Oxidative insults to neurons and synapse are prevented by aged garlic extract and S‐allyl‐l‐cysteine treatment in the neuronal culture and APP‐Tg mouse model , 2011, Journal of neurochemistry.
[79] Chengjie Xiong,et al. YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.
[80] A. Orekhov,et al. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease , 2010, Lipids in Health and Disease.
[81] R. Ransohoff,et al. Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.
[82] M. Megna,et al. Cytokine polymorphisms and Alzheimer disease: possible associations , 2010, Neurological Sciences.
[83] 김경욱,et al. 구강편평상피암종에서 stromal cell-derived factor-1의 발현 , 2010 .
[84] B. Ray,et al. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. , 2009, Current opinion in pharmacology.
[85] G. Halliday,et al. Monocyte Chemoattractant Protein‐1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease , 2009, Brain pathology.
[86] Xudong Huang,et al. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. , 2009, Biochimica et biophysica acta.
[87] S. Amini,et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[88] L. Lue,et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway , 2009, Neurobiology of Disease.
[89] V. Perry,et al. Microglial physiology: unique stimuli, specialized responses. , 2009, Annual review of immunology.
[90] C. Sen,et al. Neuroprotective and antiinflammatory properties of a novel demethylated curcuminoid. , 2009, Antioxidants & redox signaling.
[91] I. Bechmann,et al. TREM2 is upregulated in amyloid plaque‐associated microglia in aged APP23 transgenic mice , 2008, Glia.
[92] Jae Woong Lee,et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation , 2008, Journal of Neuroinflammation.
[93] F. Sánchez-García,et al. Cytokine IL‐1 beta but not IL‐1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain , 2008, European journal of neurology.
[94] F. Schmidt. Meta-Analysis , 2008 .
[95] Veer Bala Gupta,et al. Anti-amyloidogenic activity of S-allyl-l-cysteine and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro , 2007, Neuroscience Letters.
[96] R. Hendrickson,et al. Molecular Biomarkers , 2007 .
[97] R. Petersen,et al. Alzheimer's disease and mild cognitive impairment. , 2007, Neurologic clinics.
[98] N. Chauhan,et al. Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. , 2006, Journal of ethnopharmacology.
[99] C. Colton,et al. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD , 2006, Journal of Neuroinflammation.
[100] A. Rombos,et al. IL-15 Is Elevated in Cerebrospinal Fluid of Patients With Alzheimer’s Disease and Frontotemporal Dementia , 2006, Journal of geriatric psychiatry and neurology.
[101] R. Mrak,et al. Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.
[102] B. Michel,et al. Oxidative Stress Level in Circulating Neutrophils Is Linked to Neurodegenerative Diseases , 2004, Journal of Clinical Immunology.
[103] R. Maccioni,et al. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. , 2004, Experimental cell research.
[104] D. Gambi,et al. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors , 2004, Experimental Gerontology.
[105] I. Romero,et al. Regulation of chemokine receptor expression in human microglia and astrocytes , 2003, Journal of Neuroimmunology.
[106] R. Mrak,et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation , 2001, Neurochemistry International.
[107] W. Liao,et al. Inflammation in Alzheimer's Disease , 1999, Science.
[108] S. Dinsmore. Treatment options for Alzheimer's disease , 1999, The Journal of the American Osteopathic Association.
[109] R. Bronson,et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[110] S. Itohara,et al. Protective Roles of γδ T Cells and Interleukin-15 in Escherichia coli Infection in Mice , 1998, Infection and Immunity.
[111] T. Springer,et al. Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. , 1997, Journal of immunology.
[112] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[113] G. Forloni,et al. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures , 1995, Neuroscience Letters.
[114] J. Parker,et al. Amyloid deposition in Alzheimer's disease. , 1993, Annals of clinical and laboratory science.
[115] L. Altstiel,et al. Cytokines in Alzheimer's disease , 1991, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[116] C. Figdor,et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. , 1990, Blood.
[117] J. Satoh,et al. Microglia express GPNMB in the brains of Alzheimer's disease and Nasu-Hakola disease. , 2019, Intractable & rare diseases research.
[118] K. Laskowska,et al. A Comparative Analysis of the Treatment of Decision-Making by or for Patients with Neurodegenerative Diseases in Four Legal Jurisdictions. , 2019, Journal of Alzheimer's disease : JAD.
[119] M. Heneka,et al. Microglia in Neurodegenerative Disorders. , 2019, Methods in molecular biology.
[120] R. Nitsch,et al. Neurodegenerative Diseases , 2018, Springer International Publishing.
[121] D. Haas. Biomarker for Alzheimer's Disease , 2018 .
[122] A. Akaike,et al. PE859, A Novel Curcumin Derivative, Inhibits Amyloid-β and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8. , 2017, Journal of Alzheimer's disease : JAD.
[123] B. Miller,et al. Amnestic mild cognitive impairment , 2017 .
[124] F. Russo,et al. Music and Memory in Alzheimer's Disease and The Potential Underlying Mechanisms. , 2016, Journal of Alzheimer's disease : JAD.
[125] C. Nicholson,et al. Clearance systems in the brain-implications for Alzheimer disease. , 2015, Nature reviews. Neurology.
[126] Xuying Liu,et al. Design, synthesis and anti-Alzheimer properties of dimethylaminomethyl-substituted curcumin derivatives. , 2014, Bioorganic & Medicinal Chemistry Letters.
[127] L. Bertram,et al. TREM 2 and Neurodegenerative Disease , 2013 .
[128] Federal de Sergipe. Cytokine Gene Polymorphisms and Alzheimer's Disease in Brazil , 2013 .
[129] T. Wyss-Coray,et al. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.
[130] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[131] C. Laske,et al. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? , 2008, Journal of Alzheimer's disease : JAD.
[132] B. Snyder. Music and memory , 2000 .
[133] S. Itohara,et al. Protective roles of gamma delta T cells and interleukin-15 in Escherichia coli infection in mice. , 1998, Infection and immunity.
[134] X. Bao. Beta-amyloid protein and Alzheimer's disease. , 1996, Chinese Medical Journal.